全文获取类型
收费全文 | 285篇 |
免费 | 59篇 |
国内免费 | 36篇 |
专业分类
综合类 | 2篇 |
化学工业 | 151篇 |
金属工艺 | 32篇 |
机械仪表 | 5篇 |
建筑科学 | 17篇 |
轻工业 | 9篇 |
无线电 | 57篇 |
一般工业技术 | 71篇 |
冶金工业 | 28篇 |
原子能技术 | 1篇 |
自动化技术 | 7篇 |
出版年
2024年 | 1篇 |
2023年 | 14篇 |
2022年 | 30篇 |
2021年 | 71篇 |
2020年 | 31篇 |
2019年 | 25篇 |
2018年 | 27篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 19篇 |
2014年 | 21篇 |
2013年 | 19篇 |
2012年 | 6篇 |
2011年 | 34篇 |
2010年 | 9篇 |
2009年 | 3篇 |
2008年 | 10篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2005年 | 4篇 |
2004年 | 7篇 |
2003年 | 2篇 |
2002年 | 4篇 |
2001年 | 1篇 |
1988年 | 1篇 |
1965年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有380条查询结果,搜索用时 15 毫秒
21.
目的:观察新辅助化疗对胃癌手术患者罗库溴铵药效学影响。方法:50例择期行开放胃癌根治术患者,ASA分级Ⅰ或Ⅱ,性别不限,年龄40~68岁,体质量56~79 kg,25例术前未做化疗(N组),25例术前行新辅助化疗(C组)。静脉诱导患者入睡后,给予罗库溴铵0.9 mg/kg,当4次成串刺激(TOF)为0时插入气管导管,T1恢复至对照值25%时追加罗库溴铵0.15 mg/kg。记录罗库溴铵起效时间(给药至T1为0时间,t1)、首剂作用时间(首次给药至T1达25%时间,t2)、临床肌松时间(T1从0恢复至25%时间,t3)、恢复指数(T1从25%恢复至75%所需时间,RI)和拔管时间(停用肌松药至T4/T1恢复至90%时间,t4)和罗库溴铵的总用量。结果:与N组相比,C组肌松药首次作用时间延长,临床肌松时间延长,术中总用量减少,恢复指数和拔管时间延长(P<0.05)。两组患者起效时间无统计学差异(P>0.05)。结论:新辅助化疗可减少术中肌松药的使用量。 相似文献
22.
Anna Liguori Alessandro De Vita Giulia Rossi Luisa Stella Dolci Silvia Panzavolta Chiara Gualandi Laura Mercatali Toni Ibrahim Maria Letizia Focarete 《International journal of molecular sciences》2022,23(6)
In the clinical management of solid tumors, the possibility to successfully couple the regeneration of injured tissues with the elimination of residual tumor cells left after surgery could open doors to new therapeutic strategies. In this work, we present a composite hydrogel–electrospun nanofiber scaffold, showing a modular architecture for the delivery of two pharmaceutics with distinct release profiles, that is potentially suitable for local therapy and post-surgical treatment of solid soft tumors. The composite was obtained by coupling gelatin hydrogels to poly(ethylene oxide)/poly(butylene terephthalate) block copolymer nanofibers. Results of the scaffolds’ characterization, together with the analysis of gelatin and drug release kinetics, displayed the possibility to modulate the device architecture to control the release kinetics of the drugs, also providing evidence of their activity. In vitro analyses were also performed using a human epithelioid sarcoma cell line. Furthermore, publicly available expression datasets were interrogated. Confocal imaging showcased the nontoxicity of these devices in vitro. ELISA assays confirmed a modulation of IL-10 inflammation-related cytokine supporting the role of this device in tissue repair. In silico analysis confirmed the role of IL-10 in solid tumors including 262 patients affected by sarcoma as a negative prognostic marker for overall survival. In conclusion, the developed modular composite device may provide a key-enabling technology for the treatment of soft tissue sarcoma. 相似文献
23.
Martina Magni Chiara Paolizzi Chiara Monfrini Cristina Vella Paolo Corradini Cristiana Carniti 《International journal of molecular sciences》2022,23(7)
Mature T-cell lymphomas (MTCLs) represent a heterogeneous group of aggressive non-Hodgkin lymphomas comprising different entities. Anthracycline-based regimens are considered the standard of care in the front-line treatment. However, responses to these approaches have been neither adequate nor durable, and new treatment strategies are urgently needed to improve survival. Genomic instability is a common feature of cancer cells and can be caused by aberrations in the DNA damage response (DDR) and DNA repair mechanisms. Consistently, molecules involved in DDR are being targeted to successfully sensitize cancer cells to chemotherapy. Recent studies showed that some hematological malignancies display constitutive DNA damage and intrinsic DDR activation, but these features have not been investigated yet in MTCLs. In this study, we employed a panel of malignant T cell lines, and we report for the first time the characterization of intrinsic DNA damage and basal DDR activation in preclinical models in T-cell lymphoma. Moreover, we report the efficacy of targeting the apical kinase ATM using the inhibitor AZD0156, in combination with standard chemotherapy to promote apoptotic cell death. These findings suggest that DDR is an attractive pathway to be pharmacologically targeted when developing novel therapies and improving MTCL patients’ outcomes. 相似文献
24.
Aneta Sevcikova Nikola Izoldova Viola Stevurkova Barbora Kasperova Michal Chovanec Sona Ciernikova Michal Mego 《International journal of molecular sciences》2022,23(1)
Understanding the mechanisms of resistance to therapy in human cancer cells has become a multifaceted limiting factor to achieving optimal cures in cancer patients. Besides genetic and epigenetic alterations, enhanced DNA damage repair activity, deregulation of cell death, overexpression of transmembrane transporters, and complex interactions within the tumor microenvironment, other mechanisms of cancer treatment resistance have been recently proposed. In this review, we will summarize the preclinical and clinical studies highlighting the critical role of the microbiome in the efficacy of cancer treatment, concerning mainly chemotherapy and immunotherapy with immune checkpoint inhibitors. In addition to involvement in drug metabolism and immune surveillance, the production of microbiota-derived metabolites might represent the link between gut/intratumoral bacteria and response to anticancer therapies. Importantly, an emerging trend of using microbiota modulation by probiotics and fecal microbiota transplantation (FMT) to overcome cancer treatment resistance will be also discussed. 相似文献
25.
26.
Maria Lucia Iacovino Chiara Carmen Miceli Marco De Felice Biagio Barone Luca Pompella Francesco Chiancone Erika Di Zazzo Giuseppe Tirino Carminia Maria Della Corte Ciro Imbimbo Ferdinando De Vita Felice Crocetto 《International journal of molecular sciences》2022,23(3)
Muscle invasive bladder cancer (MIBC) is a widespread malignancy with a worse prognosis often related to a late diagnosis. For early-stage MIBC pts, a multidisciplinary approach is mandatory to evaluate the timing of neoadjuvant chemotherapy (NAC) and surgery. The current standard therapy is platinum-based NAC (MVAC-methotrexate, vinblastine, doxorubicin, and cisplatin or Platinum–Gemcitabine regimens) followed by radical cystectomy (RC) with lymphadenectomy. However, preliminary data from Vesper trial highlighted that dose-dense NAC MVAC is endowed with a good pathological response but shows low tolerability. In the last few years, translational-based research approaches have identified several candidate biomarkers of NAC esponsiveness, such as ERCC2, ERBB2, or DNA damage response (DDR) gene alterations. Moreover, the recent consensus MIBC molecular classification identified six molecular subtypes, characterized by different sensitivity to chemo- or targeted or immunotherapy, that could open a novel procedure for patient selection and also for neoadjuvant therapies. The Italian PURE-01 phase II Trial extended data on efficacy and resistance to Immune Checkpoint Inhibitors (ICIs) in this setting. In this review, we summarize the most relevant literature data supporting NAC use in MIBC, focusing on novel therapeutic strategies such as immunotherapy, considering the better patient stratification and selection emerging from novel molecular classification. 相似文献
27.
Shinji Miwa Norio Yamamoto Katsuhiro Hayashi Akihiko Takeuchi Kentaro Igarashi Hiroyuki Tsuchiya 《International journal of molecular sciences》2022,23(3)
Simple SummaryChondrosarcomas develop chemoresistance to standard anticancer drugs, making it difficult to control unresectable or metastatic chondrosarcomas. To improve the clinical outcomes of chondrosarcoma, new treatment approaches, such as molecule-targeting agents and immunotherapy, are needed. Recent research has revealed promising biomarkers and therapeutic targets for chondrosarcoma. In addition, several molecule-targeting agents have shown favorable antitumor activities in several clinical studies in patients with advanced sarcomas, including chondrosarcoma. This review summarizes recent basic studies on biomarkers and therapeutic targets and recent clinical studies on treating chondrosarcomas.AbstractDue to resistance to standard anticancer agents, it is difficult to control the disease progression in patients with metastatic or unresectable chondrosarcoma. Novel therapeutic approaches, such as molecule-targeting drugs and immunotherapy, are required to improve clinical outcomes in patients with advanced chondrosarcoma. Recent studies have suggested several promising biomarkers and therapeutic targets for chondrosarcoma, including IDH1/2 and COL2A1. Several molecule-targeting agents and immunotherapies have shown favorable antitumor activity in clinical studies in patients with advanced chondrosarcomas. This review summarizes recent basic studies on biomarkers and molecular targets and recent clinical studies on the treatment of chondrosarcomas. 相似文献
28.
Haina Tian Ruifeng Zhang Jiaqi Li Cailin Huang Wen Sun Zhenqing Hou Peiyuan Wang 《International journal of molecular sciences》2022,23(3)
Owing to their good stability and high photothermal conversion efficiency, the development of carbon-based nanoparticles has been intensively investigated, while the limitation of unsatisfactory cellular internalization impedes their further clinical application. Herein, we report a novel strategy for fabrication of Fe3O4 yolk–shell mesoporous carbon nanocarriers (Fe3O4@hmC) with monodispersity and uniform size, which presented significantly higher cell membrane adsorption and cellular uptake properties in comparison with common solid silica-supported mesoporous carbon nanoparticles with core–shell structure. Moreover, the MRI performance of this novel Fe-based nanoparticle could facilitate precise tumor diagnosis. More importantly, after DOX loading (Fe3O4@hmC-DOX), owing to synergistic effect of chemo–phototherapy, this therapeutic agent exhibited predominant tumor cell ablation capability under 808 nm NIR laser irradiation, both in vitro and in vivo. Our work has laid a solid foundation for therapeutics with hollowed carbon shell for solid tumor diagnosis and therapy in clinical trials. 相似文献
29.
Guosheng Song Qian Wang Yang Wang Gang Lv Chun Li Rujia Zou Zhigang Chen Zongyi Qin Keke Huo Ronggui Hu Junqing Hu 《Advanced functional materials》2013,23(35):4281-4292
Copper chalcogenides have been demonstrated to be a promising photothermal agent due to their high photothermal conversion efficiency, synthetic simplicity, and low cost. However, the hydrophobic and less biocompatible characteristics associated with their synthetic processes hamper widely biological applications. An alternative strategy for improving hydrophilicity and biocompatibility is to coat the copper chalcogenide nanomaterials with silica shell. Herein, the rational preparation design results in successful coating mesoporous silica (mSiO2) on as‐synthesized Cu9S5 nanocrystals, forming Cu9S5@mSiO2‐PEG core‐shell nanostructures. As‐prepared Cu9S5@mSiO2‐PEG core‐shell nanostructures show low cytotoxicity and excellent blood compatibility, and are effectively employed for photothermal ablation of cancer cells and infrared thermal imaging. Moreover, anticancer drug of doxorubicin (DOX)‐loaded Cu9S5@mSiO2‐PEG core‐shell nanostructures show pH sensitive release profile and are therefore beneficial to delivery of DOX into cancer cells for chemotherapy. Importantly, the combination of photothermal‐ and chemotherapies demonstrates better effects of therapy on cancer treatment than individual therapy approaches in vitro and in vivo. 相似文献
30.
Kaname Uno Shohei Iyoshi Masato Yoshihara Kazuhisa Kitami Kazumasa Mogi Hiroki Fujimoto Mai Sugiyama Yoshihiro Koya Yoshihiko Yamakita Akihiro Nawa Tomohiro Kanayama Hiroyuki Tomita Atsushi Enomoto Hiroaki Kajiyama 《International journal of molecular sciences》2022,23(8)
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and has a unique metastatic route using ascites, known as the transcoelomic root. However, studies on ascites and contained cellular components have not yet been sufficiently clarified. In this review, we focus on the significance of accumulating ascites, contained EOC cells in the form of spheroids, and interaction with non-malignant host cells. To become resistant against anoikis, EOC cells form spheroids in ascites, where epithelial-to-mesenchymal transition stimulated by transforming growth factor-β can be a key pathway. As spheroids form, EOC cells are also gaining the ability to attach and invade the peritoneum to induce intraperitoneal metastasis, as well as resistance to conventional chemotherapy. Recently, accumulating evidence suggests that EOC spheroids in ascites are composed of not only cancer cells, but also non-malignant cells existing with higher abundance than EOC cells in ascites, including macrophages, mesothelial cells, and lymphocytes. Moreover, hetero-cellular spheroids are demonstrated to form more aggregated spheroids and have higher adhesion ability for the mesothelial layer. To improve the poor prognosis, we need to elucidate the mechanisms of spheroid formation and interactions with non-malignant cells in ascites that are a unique tumor microenvironment for EOC. 相似文献